What to Watch in The Day Ahead; Tuesday, April 22
(The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at . Thomson One users can register at RT/DAY/US. All times in ET/GMT) United Technologies is scheduled to report first-quarter results. The large U.S. manufacturer of elevators, climate control systems, jet engines and other aerospace equipment told investors last month that first-quarter earnings were likely to fall short of the average analyst estimate.
Property and casualty insurer Travelers Cos is expected to post first-quarter results above estimates, according to StarMine data. Travelers has benefited from lower disaster losses and rising insurance rates. Investors, however, will be interested to know whether the company's ability to hike premium rates is showing any signs of slowing.
McDonald's Corp is likely to blame extreme winter weather for weakness when it reports first-quarter earnings. Analysts will be expecting the management to explain why it can't seem to get any sales growth.
AT&T is scheduled to report first-quarter results. In the previous quarter, its wireless subscriber growth and its free cash flow target lagged well behind analyst estimates.
Home resales were likely flat in March, after falling 0.4 percent in February, the National Association of Realtors is expected to report. Sales of previously owned homes are expected to have declined to 4.55 million units in March from February's 4.60 million units. (1000/1400)
Comcast, which is trying to win approval from U.S. regulators for its $45.3 billion takeover of Time Warner Cable, is expected to report first-quarter results before the bell. Investors will be listening for any commentary on what it plans to do with divestitures related to the deal and whether it can post another sequential gain in video subscriber growth.
Amgen is expected to report first-quarter results after the bell. Sales likely received a boost from the rheumatoid arthritis drug, Enbrel, for which the company regained full rights following the end of a revenue-sharing arrangement with Pfizer. Investors will be looking for an update to full-year forecast after what was seen as a conservative outlook issued in January, as well as details on the biotech company's developmental pipeline and plans for seeking approvals for its high profile new cholesterol drug, evolocumab.
Gilead Sciences is likely to post first-quarter results. It posted a better-than-expected quarterly profit in the fourth quarter as sales of its flagship HIV drugs beat Wall Street estimates. (1605/2005)
Lockheed Martin, maker of F-35 fighter jets, satellites and warships, is scheduled to report first-quarter results before the markets open. It had forecast higher earnings in 2014 after charges linked to U.S. defense budget cuts and workforce reductions depressed earnings in the fourth quarter. Continued...